- Ph.D., Georgia Institute of Technology, 1986
Principal Research Interests
Environmental toxins and Parkinson’s disease:
Although the exact cause(s) of dopaminergic cell death in Parkinson's disease (PD) is not understood, the commonly accepted view is that the exposure to environmental toxins may be a major cause of PD, especially in individuals with cumulative defects in pathways associated with handling of oxidative stress, mitochondrial function, calcium homeostasis, and the ubiquitin proteasome system. The discovery that 1-methyl-4-phenylpyridinium (MPP+) selectively destroys dopaminergic neurons and causes PD symptoms in humans and other mammals has strengthened the environmental hypothesis of PD. Therefore, MPP+ has been extensively used to model the environmental causes of PD. The current model for the selective dopaminergic toxicity of MPP+ is centered on the specific cellular uptake into dopaminergic cells through the plasma membrane dopamine transporter (DAT) , complex I inhibition leading to ATP depletion, increased reactive oxygen species (ROS) production, and finally apoptotic cell death. However, we have shown that MPP+ is taken up not only into dopaminergic cells, but also into various other cells, including liver cells, through various other transporters with high efficiency. Thus, the selective dopaminergic toxicity of MPP+ could not be due to the specific uptake into dopaminergic cells through DAT. The focus of current research in my lab is to determine the molecular causes of specific degeneration of the dopaminergic system in PD. Specifically we are interested in:
- Identification of environmental causes and mechanisms of dopaminergic degeneration in PD.
- Determination of the role of Ca2+ in mitochondrial accumulation and toxicity of Parkinsonian toxins.
- Determination of the role of catecholamines in the inherent vulnerability of dopaminergic neurons towards mitochondrial toxins.
- Answering the question “Does intracellular acidosis mediated TH activation play a role in selective dopaminergic cell death in PD and other neurodegenerative diseases?”
- Kadigamuwa, C. C., Mapa, S. T., Wimalasena, K. “Lipophilic Cationic Cyanines Are Potent Complex I Inhibitors and Specific in Vitro Dopaminergic Toxins with Mechanistic Similarities to Both Rotenone and MPP+” Chem. Res. Toxicol. (ACS), 2016, 28, 1468-1479.
- Wimalasena, N. K., Viet, Q. L., Wimalasena, K., Schreiber, S. L., Karmacharya, R. “Gene Expression-Based Screen for Parkinson’s Disease Identifies GW8510 as a Neuroprotective Agent” ACS Chem. Neurosci, 2016, 7, 857-863
- Freyberg, Z., Sonders, M., Aguilar, J., Hiranita, T., Karam, C., Flores, J., Pizzo, A., Zhang, Y., Farino, Z., Chen, A., Martin, C., Kopajtic, T., Fei, H., Hu, G., Lin, Y-Y., Mosharov, E., McCabe, B., Freyberg, R., Wimalasena, K., Hsin, L-W., Sames,D., Krantz, D., Katz, J., Sulzer, D., Javitch, J." Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain" Nature Communications 2016, 7, Article # 10652, 1-15.
- Wimalasena, K. “The inherent high vulnerability of dopaminergic neurons towards mitochondrial toxins may contribute to the etiology of Parkinson’s disease (PD)” Neural Regeneration Research 2016, 11, 246-247 Invited Perspective.
- Kadigamuwa, C. C., Le, V. Q., Wimalasena, K. “ 2,2- and 4, 4-Cyanines are transporter independent in vivo dopaminergic toxins with the specificity and mechanism of toxicity similar to MPP+” J. Neurochemistry, 2015, 135, 755-767.
- Wimalasena, K. “Vesicular monoamine transporters: Structure/Function and Pharmacology” Invited Review Medicinal Research Reviews 2011, 31, 483-519 (Invited Review).
- Wimalasena, D. S., Perera, R. P., Heyen, B. J., Wimalasena , K. “Vesicular Monoamine Transporter Substrate/Inhibitor activity of MPP+ Derivatives: A Structure-Activity Study" J. Med. Chem. 2008, 51, 760-768.
- Samms, W. C., Perera, R. P., Wimalasena, D. S., Wimalasena, K. “Perturbation of Dopamine Metabolism by 3-Amino-2-(4'-Halophenyl)propenes Leads to Increased Oxidative Stress and Apoptotic SH-SY5Y Cell Death” Mol. Pharmacol. 2007, 72, 744-752.
- Wimalasena, D. S., Wiese, T. J., Wimalasena, K. “Copper Ions Disrupt Dopamine Metabolism via Inhibition of V-H+-ATPase: A Possible Contributing Factor to Neurotoxicity J. Neurochem. 2007, 101, 313-326.